Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A2102 + Adebrelimab in Early TNBC
NCT06819319Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of SHR-A2102 in triple-negative breast cancer (TNBC), sponsored by Henan Cancer Hospital. Primary endpoint: Pathologic Complete Response Rate. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
SHR-A2102
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06819319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06819319.